de Verneuil Vanina sold $42K of VIR
de Verneuil Vanina (EVP, General Counsel, Corp Sec) sold 3,750 shares of Vir Biotechnology, Inc. (VIR) at an average of $11.18 ($11.10–$11.33) across 2 trades over 2026-11-02 to 2026-11-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to move the stock significantly, but it provides a data point for monitoring insider activity.
Market read
A routine insider sale with limited immediate market impact; useful for compliance and monitoring purposes.
What to watch
Potential upcoming clinical data releases or partnership announcements could offset the sell‑off.
Background
Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.
Ticker impact
EVP and General Counsel de Verneuil Vanina sold 3,750 shares of Vir Biotechnology for $41,939 via a 10b5‑1 plan, reducing his stake to 110,193 shares.
likely slight downward pressure as the market prices the insider sell.
The sale amount is modest relative to the company's market cap, but insider sales can prompt short‑term caution.
Market effects
Minimal impact on the broader biotech sector; the filing is company‑specific.
No discernible regional effect.
Limited to investors tracking Vir Biotechnology.
Counterpoint
The sale could be routine under a pre‑arranged plan and not indicative of negative fundamentals.
Key entities
- CompanyVir Biotechnology, Inc.
US‑listed biotech firm developing antiviral therapies.
- Individualde Verneuil Vanina
Executive Vice President, General Counsel, and Corporate Secretary at Vir.
